Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists
- 7 March 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 21 (4) , 539-548
Abstract
Introduction: The relationship between clinical outcomes and serum anti-TNF levels is controversial. The aim of this study was to perform simultaneous analyses of serum, mucosal and faecal anti-TNF-α levels. Methods: Consecutive IBD patients who received maintenance anti-TNF-α therapy were enrolled. The number of TNF-α positive cells in the mucosa was detected using immunofluorescent labelling on biopsy samples. Serum, mucosal and faecal anti-TNF-α, serum anti-drug antibody and faecal calprotectin levels were determined using ELISA. Each patient underwent body composition analysis as well. Results: Data of 50 patients was analysed. The number TNF-α positive cells was significantly higher in the inflamed than in the un-inflamed part of the colon. Tissue and faecal drug levels did not show any association with serum drug levels, moreover serum anti-TNF concentration did not correlate with endoscopic activity. Mucosal anti-TNF levels were higher only in IFX-treated patients in remission and IFX-treated patients with detectable faecal anti-TNF had lower tissue drug levels. Presence of the drug in the faeces was significantly different according to disease activity. Conclusion: Faecal drug concentration is suggested to be a better predictor of endoscopic activity and loss of response and faecal drug monitoring may improve the estimation accuracy of tissue drug levels.Keywords
Funding Information
- National Research
This publication has 24 references indexed in Scilit:
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS studyGut, 2015
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2014
- Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled TrialAmerican Journal of Gastroenterology, 2014
- In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's diseaseNature Medicine, 2014
- Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel diseaseWorld Journal of Gastroenterology, 2014
- Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically usefulGut, 2010
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976